您当前所在的位置:首页 > 产品中心 > 产品信息
PF-2545920_分子结构_CAS_1292799-56-4)
点击图片或这里关闭

PF-2545920

产品号 S2687 公司名称 Selleck Chemicals
CAS号 1292799-56-4 公司网站 http://www.selleckchem.com
分子式 C25H20N4O 电 话 (877) 796-6397
分子量 392.4525 传 真 (832) 582-8590
纯 度 电子邮件 sales@selleckchem.com
保 存 -20°C Chembase数据库ID: 6003

产品价格信息

请登录

产品别名

标题
PF-2545920
IUPAC标准名
2-{4-[1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]phenoxymethyl}quinoline
IUPAC传统名
2-{4-[1-methyl-4-(pyridin-4-yl)pyrazol-3-yl]phenoxymethyl}quinoline

产品登记号

CAS号 1292799-56-4

产品性质

作用靶点 PDE
成盐信息 Free Base
保存条件 -20°C

产品详细信息

详细说明 (English)
Research Area
Description Schizophrenia
Biological Activity
Description PF-2545920 is a potent and selective PDE10A inhibitor with IC50 of 0.37 nM.
Targets PDE10A
IC50 0.37 nM [2]
In Vitro MP-10 shows excellent potency and selectivity of PDE10A with IC50 of 1.26 nM. [1]
In Vivo MP-10 intraperitoneally administrated at dose of 0.3, 3, and 5 mg/kg in male CF-1 mice causes striking increases in GluR1 phosphorylation levels of 3-, 5.4-, and 4.1-fold , respectively. MP-10 at concentration of 1 μM treats Rat striatal slices for 30 min, the level of GluR1S845 phosphorylation at the cell surface is significantly increased 2-fold, without change the level of total GluR1 on the cell surface. MP-10 intraperitoneally administrated at dose of 0.3, 3, and 5 mg/kg in male CF-1 mice results in robust, statistically significant increases in CREBS133 phosphorylation of 3-, 4-, and 2.6-fold, respectively. MP-10 intraperitoneally administrated at dose of 3 mg/kg increases both enkephalin and substance-P mRNA levels in striatum of CF-1 mice. MP-10 intraperitoneally administrated at dose of 0.3–1 mg/kg decreases avoidance responding with a significant treatment effect in the mouse CAR model. Mice treated with MP-10 at dose of 0.03 mg/kg spents more time in the empty than social side in the mice, MP-10 also dose-dependently decreased locomotor activity. [1] PDE10A subcutaneously administrated at dose of 1 mg/kg elevates striatal cGMP about 3 fold in male CD-1 mice, while PDE10A subcutaneously administrated at dose of 3.2 mg/kg displays a maximal elevation of striatal cGMP approximately a 5-fold increase in male CD-1 mice. PDE10A intravenous injected at a dose of 0.1 mg/kg in Sprague-Dawley rats displays clearance of 36 ml/min/Kg, DE10A intravenous injected at a dose of 0.3 mg/kg in Dog Beagle displays clearance of 7.2 ml/min/Kg in vivo clearance with a moderate volume of distribution, DE10A intravenous injected at a dose of 0.03 mg/kg in Monkey Cynomolgus displays clearance of 13.9 ml/min/Kg in vivo clearance with a moderate volume of distribution. PDE10A is active with an ED50 of 1 mg/kg at a significantly lower total plasma exposure (115 nM) in the conditioned avoidance response assay (CAR) in Sprague-Dawley rats. [2]
Clinical Trials
Features
References
[1] Grauer SM, et al. J Pharmacol Exp Ther, 2009, 331(2), 574-590.
[2] Verhoest PR, et al. J Med Chem, 2009, 52(16), 5188-5196.